


<b>Name of Policy:</b>	<u><b>Definity (Perflutren Lipid Microsphere)</b></u>	
<b>Policy Number:</b>	3364-106-E10	
<b>Department:</b>	Heart Station	
<b>Approving Officer:</b>	Chief Operating Officer - UTMC	
<b>Responsible Agent:</b>	Director Cardiovascular Services	
<b>Scope:</b>	University of Toledo Medical Center Heart Station	<b>Effective Date:</b> 03/2022 <b>Initial Effective Date:</b> 6/20/2002
<input type="checkbox"/> New policy proposal <input type="checkbox"/> Minor/technical revision of existing policy <input type="checkbox"/> Major revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy		

**(A) Policy Statement**

The ECHO Technologist will provide safe and effective care when using Definity contrast on a patient in a manner to insure that quality care is given and quality results are achieved.

**(B) Purpose of Policy**

Activated Definity injectable suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial borders. Activated Definity can be used during Exercise Stress, Dobutamine Stress, Resting Echocardiograms and Trans esophageal Echocardiograms.

**(C) Procedure**

**Criteria for Definity Usage**

Basic criteria may include, but not limited to, the following:

1. Stress Echocardiogram-Definity may be used if two or more of left ventricular wall segments are poorly visualized on the baseline views.
2. Transthoracic/Trans esophageal Echocardiograms-Definity may be used if two or more left ventricular wall segments are poorly visualized or if apical views are suspicious for a thrombus. Definity may also be used to enhance Doppler signals. Definity may also be used to assess for aortic dissection.

**Contraindications**

- Do not administer Definity to patients with known or suspected hypersensitivity to Perflutren.

**Warnings and Precautions**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Always have resuscitation equipment and trained personnel readily available.

**Adverse Reactions**

The most common adverse reactions (>0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.

Protocol

If the criteria for Definity use are met as mentioned above, the following will be implemented:

1. The sonographer or physician will assess the need for Definity in compliance with the procedure.
2. The physician will oversee the order.
3. The RN or Nuclear Technologist should be contacted to start the IV if needed.
4. Use bolus of Definity.
5. The RN or physician will inject the activated Definity.
6. Remove IV and release patient if asymptomatic.

<b>Approved by:</b>  <u>/s/</u> Todd Korzec Director Cardiovascular Services  <u>/s/</u> Samer J. Khouri, MD Director, Non-invasive Cardiac Imaging  <u>/s/</u> Christine Stesney-Ridenour, FACHE Chief Operating Officer- UTMC  <i>Review/Revision Completed By: Todd Korzec Heart Station</i>	<b>Review/Revision Date:</b> 5/04 6/05 7/07 10/07 1/09 8/25/2010 6/2013 3/2016 10/2019 03/2022
	<b>Next Review Date:</b> 03/2025
<b>Policies Superseded by This Policy:</b>	